Nuvation Bio, Inc. (NUVB)

NYSEHealth CareBiotechnologySnapshot 2026-10-23

$4.57-2.77%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Nuvation Bio, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	45.26M
EPS	—	-0.115
Annual ending 2026-12-31
Revenue	—	194.5M
EPS	—	-0.403
Annual ending 2027-12-31
Revenue	—	274.79M
EPS	—	-0.211

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage new debt from $250 million offering without hurting growth	A supporting condition in Nuvation Bio, Inc.'s published investment case. The stated target is Debt managed without harming growth or cash flow.	Intact	Debt causes cash flow problems or growth stalls	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Net income positive at $5.397 million in 2026-Q1	It made $5.4 million net income in 2026-Q1.	Broken	Net income falls below zero in 2026-Q1	Net income: $-62.84M FY2026-Q2; GAAP. Published target: >=5.397 USD_MILLIONS. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 6, 2026-62,840,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: d3615da9-7b74-417d-87cc-b750c6aa02f9. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Net income was positive $5.4 million in 2026-Q1 but declined to a net loss of $62.8 million in 2026-Q2. Despite revenue growth, profitability deteriorated in Q2, indicating limited progress on sustained positive net income. Delivery assessment Oct 24, 2026
Revenue reaches at least $83.23 million in 2026	A primary condition in Nuvation Bio, Inc.'s published investment case. The stated target is >=83.23 USD_MILLIONS.	Intact	Revenue falls below $83 million in FY26	Revenue: $31.687M FY2026-Q2; GAAP. Published target: >=83.23 USD_MILLIONS. Target period is not explicitly aligned with this observation. Source published Aug 6, 202631,687,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: d3615da9-7b74-417d-87cc-b750c6aa02f9. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain strategic partnership with Eisai for drug development	The company has a deal with Eisai to develop a cancer drug.	Intact	Partnership with Eisai ends or fails	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.21

Unavailable → $-0.21 · observed estimates

FY2027 revenue$0.27B

$0.29B → $0.27B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$289,918,500	1 / 9
2026-07-25	Unavailable	$289,918,500	1 / 9
2026-07-26	Unavailable	$289,918,500	1 / 9
2026-07-27	Unavailable	$289,918,500	1 / 9
2026-07-28	Unavailable	$287,948,691	4 / 6
2026-07-29	Unavailable	$289,918,500	1 / 9
2026-07-30	Unavailable	$289,918,500	1 / 9
2026-07-31	Unavailable	$289,918,500	1 / 9
2026-08-01	Unavailable	$287,948,691	4 / 6
2026-08-02	Unavailable	$287,948,691	4 / 6
2026-08-03	Unavailable	$289,918,500	1 / 9
2026-08-04	Unavailable	$289,918,500	1 / 9
2026-08-05	Unavailable	$288,387,435	4 / 6
2026-08-06	Unavailable	$288,387,435	4 / 6
2026-08-07	Unavailable	$288,387,435	4 / 6
2026-08-08	$-0.24	$288,947,830	7 / 9
2026-08-09	Unavailable	$288,387,435	4 / 6
2026-08-10	Unavailable	$288,387,435	4 / 6
2026-08-12	Unavailable	$288,387,435	4 / 6
2026-08-13	Unavailable	$281,702,210	1 / 9
2026-08-14	Unavailable	$288,387,435	4 / 6
2026-08-15	Unavailable	$288,387,435	4 / 6
2026-08-16	Unavailable	$288,387,435	4 / 6
2026-08-17	Unavailable	$288,387,435	4 / 6
2026-08-18	Unavailable	$288,387,435	4 / 7
2026-08-19	Unavailable	$288,387,435	4 / 7
2026-08-20	$-0.19	$287,174,491	5 / 7
2026-08-21	$-0.19	$287,174,491	5 / 8
2026-08-22	$-0.19	$282,426,616	6 / 8
2026-08-23	$-0.19	$282,426,616	6 / 9
2026-08-24	$-0.19	$282,426,616	6 / 9
2026-08-25	$-0.19	$282,426,616	6 / 9
2026-08-26	$-0.19	$282,426,616	6 / 9
2026-08-27	$-0.19	$282,426,616	6 / 9
2026-08-28	$-0.19	$282,426,616	6 / 9
2026-08-29	$-0.19	$282,426,616	6 / 9
2026-08-30	$-0.19	$282,426,616	6 / 9
2026-08-31	$-0.19	$282,426,616	6 / 9
2026-09-01	$-0.19	$282,426,616	6 / 9
2026-09-02	$-0.19	$282,426,616	6 / 9
2026-09-03	$-0.19	$282,426,616	6 / 9
2026-09-04	$-0.19	$282,426,616	6 / 9
2026-09-05	$-0.19	$282,426,616	6 / 9
2026-09-06	$-0.19	$282,426,616	6 / 9
2026-09-07	$-0.19	$282,426,616	6 / 9
2026-09-08	$-0.19	$282,426,616	6 / 9
2026-09-09	$-0.19	$282,426,616	6 / 9
2026-09-10	$-0.19	$282,426,616	6 / 9
2026-09-11	$-0.19	$282,426,616	6 / 9
2026-09-12	$-0.19	$282,426,616	6 / 9
2026-09-13	$-0.19	$282,426,616	6 / 9
2026-09-14	$-0.19	$282,426,616	6 / 9
2026-09-15	$-0.19	$282,426,616	6 / 9
2026-09-16	$-0.19	$282,426,616	6 / 9
2026-09-17	$-0.19	$278,851,616	6 / 9
2026-09-18	$-0.19	$278,851,616	6 / 9
2026-09-19	$-0.19	$278,851,616	6 / 9
2026-09-20	$-0.19	$278,851,616	6 / 9
2026-09-21	$-0.19	$278,851,616	6 / 9
2026-09-22	$-0.19	$278,851,616	6 / 9
2026-09-23	$-0.19	$278,851,616	6 / 9
2026-09-24	$-0.19	$278,851,616	6 / 9
2026-09-25	$-0.19	$278,034,950	6 / 9
2026-09-26	$-0.19	$278,034,950	6 / 9
2026-09-27	$-0.19	$278,034,950	6 / 9
2026-09-28	$-0.19	$278,034,950	6 / 9
2026-09-29	$-0.19	$278,034,950	6 / 9
2026-09-30	$-0.19	$278,034,950	6 / 9
2026-10-01	$-0.18	$283,921,720	6 / 9
2026-10-02	$-0.18	$283,921,720	7 / 10
2026-10-03	$-0.18	$283,921,720	7 / 10
2026-10-04	$-0.18	$283,921,720	7 / 10
2026-10-05	$-0.18	$283,921,720	7 / 10
2026-10-06	$-0.18	$283,921,720	7 / 10
2026-10-07	$-0.18	$283,921,720	7 / 10
2026-10-08	$-0.18	$283,921,720	7 / 10
2026-10-09	$-0.18	$283,921,720	7 / 10
2026-10-10	$-0.18	$283,921,720	7 / 10
2026-10-11	$-0.18	$283,921,720	7 / 10
2026-10-12	$-0.18	$283,921,720	7 / 10
2026-10-13	$-0.19	$281,667,413	7 / 10
2026-10-14	$-0.19	$281,667,413	7 / 10
2026-10-15	$-0.19	$281,667,413	7 / 10
2026-10-16	$-0.19	$281,667,413	7 / 10
2026-10-17	$-0.19	$281,667,413	7 / 10
2026-10-18	$-0.19	$281,667,413	7 / 10
2026-10-19	$-0.19	$281,667,413	7 / 10
2026-10-20	$-0.19	$282,675,105	7 / 10
2026-10-21	$-0.19	$282,675,105	7 / 10
2026-10-22	$-0.21	$274,793,962	7 / 10
2026-10-23	$-0.21	$274,793,962	7 / 10
2026-10-24	$-0.21	$274,793,962	7 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	9	1
2026-06-01	9	1
2026-07-01	9	1
2026-08-01	11	1
2026-09-01	12	1
2026-10-01	12	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 12 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage new debt from $250 million offering without hurting growthQualitative condition
Net income positive at $5.397 million in 2026-Q1Published status: Broken
Revenue reaches at least $83.23 million in 2026Revenue: $31.687M
Maintain strategic partnership with Eisai for drug developmentQualitative condition

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-57.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Nuvation Bio, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

NUVB is a high-risk, loss-making biopharmaceutical company with a growth and development thesis, rather than an established earnings compounder. The long-term thesis is intact, supported by recent IBTROZI growth, while progress on other priorities remains mixed.

What's priced into Nuvation Bio, Inc.

The evidence describes NUVB as cheap versus peers, with no premium indicated, but model confidence is low. The expectations gap is modestly negative, and the priced-in status is tagged justified with low fragility, so the snapshot does not point to extreme expectations either way.

What the fundamentals likely do

Near term, IBTROZI revenue and adoption are growing, and the latest reported earnings were in line; however, the business remains loss-making and the chance of a near-term miss is worth watching. Over the multi-year view, clinical development and commercialization progress matter, but management’s delivery on the DDC platform and safusidenib remains mixed.

What Nuvation Bio, Inc. hinges on

The thesis depends on continued IBTROZI adoption and execution of the safusidenib program, including its clinical studies. Near term, a guidance cut or further weakening in jobs data would add pressure, while continued strength from healthcare bellwethers could support sector momentum.